Foscan PDT治疗顽固性头颈部肿瘤展露头角

Biolitec公司生产的光敏剂Foscan ® ，用于治疗顽固性头颈部肿瘤，Foscan已经获得欧洲药物管制和欧洲联盟委员会的批准，Biolitecs新工厂在苏格兰。 Foscan ®是光敏剂（光敏感的药物） ，其中包含temoporfin可用于光动力疗法，给广大的顽固性头颈部肿瘤患者带来福音。南方医科大学南方医院肿瘤科李黎波

In October 2001, Foscan® was approved in the European Union, Norway & Iceland as a local therapy for the palliative treatment of patients with advanced head and neck cancer who have failed prior therapies and are unsuitable for radiotherapy, surgery or systemic chemotherapy.The aims of treatment with Foscan® may include preservation of organ function, local tumour destruction, relief of symptoms and avoidance of disease-related complications.As part of the PDT process, Foscan® requires oxygen and laser light of a specific wavelength of 652 nm for activation.There is a delay of 4 days between injection of Foscan® into the bloodstream and activation with laser light.This allows time for accumulation of Foscan® in the cancer cells.As with other photosensitizing agents, administration of Foscan® results in patients becoming highly sensitive to light.For Foscan® , the period of sensitivity is approximately 15 days and, therefore, appropriate light exposure precautions should be followed during this period.